

**DEPARTMENT OF DEFENSE
PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS**

August 2013

Addendum

I. UNIFORM FORMULARY (UF) DRUG CLASS REVIEWS—Self-Monitoring Blood Glucose System (SMBGS) Test Strips

The Pharmacy and Therapeutics (P&T) Committee reviewed the clinical effectiveness of the SMBGS test strips at the May 2013 P&T Committee meeting. The cost effectiveness, Uniform Formulary (UF) recommendation, Basic Core Formulary (BCF) recommendation, Prior Authorization (PA) criteria, Medical Necessity (MN) criteria, quantity limits (QLs), and implementation period were presented at the August 2013 P&T Committee meeting. An implementation period for the final decisions of 180 days, effective May 7, 2014, was approved by the Director, DHA, on November 7, 2013.

All steps necessary for implementation of the SMBGS test strips decisions were delayed 100 days, due to a GAO protest, which was dismissed on March 5, 2014. Due to the delay, the implementation period is extended to August 6, 2014, to allow for adequate time for DHA to implement the decisions and to send a letter to beneficiaries affected by the UF and PA decisions. There is no change to the other decisions for the SMBGS test strips.



Douglas J. Robb, DO, MPH
Lieutenant General, USAF, MC, CFS
Director

29 Apr 2014

Date